JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.23 -1.6

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.22

Máximo

1.25

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+111.9% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.2M 80M
Apertura anterior	2.83
Cierre anterior	1.23

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

Intertek Group Rejects EQT's Revised Offer

24 abr 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Scoring the Cook Era -- Barrons.com

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:09 UTC

Ganancias

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 abr 2026, 19:48 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 abr 2026, 19:22 UTC

Ganancias

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 abr 2026, 19:06 UTC

Ganancias

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 abr 2026, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 abr 2026, 18:30 UTC

Adquisiciones, fusiones, absorciones

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 abr 2026, 18:28 UTC

Adquisiciones, fusiones, absorciones

Intertek Rejects Revised EQT Offer

24 abr 2026, 18:12 UTC

Charlas de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 abr 2026, 18:06 UTC

Charlas de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 abr 2026, 17:42 UTC

Ganancias

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 abr 2026, 17:28 UTC

Ganancias

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 abr 2026, 17:28 UTC

Charlas de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 abr 2026, 17:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 abr 2026, 17:11 UTC

Charlas de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 abr 2026, 17:09 UTC

Charlas de Mercado

Ganancias

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:06 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 abr 2026, 16:51 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 abr 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

24 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

111.9% repunte

Estimación a 12 Meses

Media 2.67 USD 111.9%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.